{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:22:14Z","timestamp":1787761334785,"version":"build-2784847793"},"reference-count":13,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2016,5,3]]},"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To analyse the treatment outcome of patients with ankylosing spondylitis (AS) in the European AS infliximab cohort (EASIC) study after a total period of 8\u2005years with specific focus on dosage and the duration of intervals between infliximab infusions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>EASIC included patients with AS who had received infliximab for 2\u2005years as part of the ASSERT trial. After that period, rheumatologists were free to change the dose or the intervals of infliximab. Clinical data were status at baseline, end of ASSERT and for a total of 8\u2005years of follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the initially 71 patients with AS from EASIC, 55 patients (77.5%) had completed the 8th year of anti-tumour necrosis factor (TNF) treatment. Of those, 48 patients (87.3%) still continued on infliximab. The mean infusion interval increased slightly from 6 to 7.1\u00b11.5\u2005weeks, while 45.8% patients had increased the intervals up to a maximum of 12\u2005weeks. The mean infliximab dose remained stable over time, with a minimum of 3.1\u2005mg\/kg and a maximum of 6.4\u2005mg\/kg. In patients receiving &lt;5\u2005mg\/kg infliximab, the mean infusion interval increased to 7.0\u00b11.2\u2005weeks. In total, the mean cumulative dose per patient and per year decreased from 3566.30 to 2973.60\u2005mg.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We could observe that over a follow-up of 8\u2005years of treatment with infliximab, &gt;85% patients still remained on the same treatment, without any major safety events. Furthermore, both the infusion intervals and also the mean infliximab dose were modestly reduced in \u226570% of the patients without the loss of clinical efficiency.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2016-000272","type":"journal-article","created":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T22:24:14Z","timestamp":1468967054000},"page":"e000272","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction"],"prefix":"10.1136","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"X","family":"Baraliakos","sequence":"first","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Herne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Heldmann","sequence":"additional","affiliation":[{"name":"Zeisigwaldkliniken Bethanien, Chemnitz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"van den Bosch","sequence":"additional","affiliation":[{"name":"Universitair Ziekenhuis, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Burmester","sequence":"additional","affiliation":[{"name":"Charit\u00e9 University Medicine Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Gaston","sequence":"additional","affiliation":[{"name":"University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I E","family":"van der Horst-Bruinsma","sequence":"additional","affiliation":[{"name":"VU Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Krause","sequence":"additional","affiliation":[{"name":"Immanuel Krankenhaus, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Medical University Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Schneider","sequence":"additional","affiliation":[{"name":"University Clinic D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Sieper","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Campus Benjamin Franklin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Andermann","sequence":"additional","affiliation":[{"name":"Private rheumatology practice, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"van Tubergen","sequence":"additional","affiliation":[{"name":"Maastricht University Medical Center, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Witt","sequence":"additional","affiliation":[{"name":"University of Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Braun","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Herne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,7,19]]},"reference":[{"key":"2025090312594699000_2.2.e000272.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7"},{"key":"2025090312594699000_2.2.e000272.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"2025090312594699000_2.2.e000272.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.20852"},{"key":"2025090312594699000_2.2.e000272.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.21790"},{"key":"2025090312594699000_2.2.e000272.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202698"},{"key":"2025090312594699000_2.2.e000272.6","doi-asserted-by":"publisher","DOI":"10.1186\/ar4244"},{"key":"2025090312594699000_2.2.e000272.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker194"},{"issue":"(4 Suppl 55)","key":"2025090312594699000_2.2.e000272.8","first-page":"S112","article-title":"The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis","volume":"27","author":"Boonen","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312594699000_2.2.e000272.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.20852"},{"key":"2025090312594699000_2.2.e000272.10","first-page":"672","article-title":"The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab","volume":"29","author":"Heldmann","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312594699000_2.2.e000272.11","first-page":"184","article-title":"Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety","volume":"34","author":"Heldmann","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312594699000_2.2.e000272.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204953"},{"key":"2025090312594699000_2.2.e000272.13","first-page":"625","article-title":"European Ankylosing Spondylitis Infliximab Cohort (EASIC): outcome of patients who had discontinued infliximab after the end of ASSERT","volume":"68","author":"Heldmann","year":"2009","journal-title":"Ann Rheum Dis"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2016-000272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:59:53Z","timestamp":1756929593000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2016-000272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,7,19]]},"published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1136\/rmdopen-2016-000272"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2016-000272","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}